Hail GSK's chairman-to-be Philip Hampton: It's a tough job ahead

Philip Hampton

It's official: GlaxoSmithKline ($GSK) tapped Royal Bank of Scotland chair Philip Hampton to take the reins as chairman. The choice comes as increasingly restive shareholders call for change at the drugmaker, plagued by corruption scandals and suffering from competition to its megablockbuster respiratory drug Advair. He'll join GSK's board Jan. 1, become deputy chair in April and move into Chairman Christopher Gent's seat in September 2015. Report

Suggested Articles

Experts say it's worth exploring whether a Roche stroke drug could help certain COVID-19 patients.

Bluebird said it doesn't expect to complete a U.S. application for the gene therapy until mid-2021 amid COVID-19 and a lack of agreement with the FDA.

A group of drugmakers and others say some federal policies to fight COVID-19 are it making more expensive and harder to get some drugs.